The ethics of synthetic biology research and development:a principlist approach

A principlist approach is adopted to analyse the ethical status of synthetic biology (synbio) research and development. The principle of nonmaleficence generates precaution-driven conclusions that are excessively restrictive to the field of synbio. The principle of beneficence is best served by permitting synbio research to flourish and not have it treated as a special case warranting the imposition of a high degree of external and self-regulation. Synbio may offend the principle of justice in certain circumstances; however, such issues are largely restricted to the initial stages of synbio innovation, whilst in the longer term the development of the field can be expected to promote just ends. The principle of respect for autonomy entails that scientists ought to be afforded a broad scope to freely pursue synbio research and development in a curiosity-driven fashion. In balancing the various conclusions under the four principles, the author concludes that society has an ethical obligation to support the development of synbio research and development and not restrict this important nascent field by the imposition of stern regulation

Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations

Intravenous and subcutaneous immunoglobulin preparations, consisting of IgG class antibodies, are increasingly used to treat a broad range of pathological conditions, including humoral immune deficiencies, as well as acute and chronic inflammatory or autoimmune disorders. A plethora of Fab- or Fc-mediated immune regulatory mechanisms has been described that might act separately or in concert, depending on pathogenesis or stage of clinical condition. Attempts have been undertaken to improve the efficacy of polyclonal IgG preparations, including the identification of relevant subfractions, mild chemical modification of molecules, or modification of carbohydrate side chains. Furthermore, plasma-derived IgA or IgM preparations may exhibit characteristics that might be exploited therapeutically. The need for improved treatment strategies without increase in plasma demand is a goal and might be achieved by more optimal use of plasma-derived proteins, including the IgA and the IgM fractions. This article provides an overview on the current knowledge and future strategies to improve the efficacy of regular IgG preparations and discusses the potential of human plasma-derived IgA, IgM, and preparations composed of mixtures of IgG, IgA, and IgM